|
|
|
|
|
|
|
16.09.26 - 13:06
|
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company's Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and experienced board director who brings deep commercial and operational expertise, as well as a proven track record of driving growth and transformation across global pharmaceutical and biotechnology organizations.
“Anne joins our Board at a defining time for Alkermes,” said Blair Jackson, President and Chief Executive Officer of Alkermes. “We are building on our strong commercial performance and advancing a differentiated pipeline that we believe has the potential to address significant unmet needs in neuroscience. Anne's experience and perspectives will be valuable assets as we execute on our strategy and work to develop new medicines for patients and create long-term value for our shareholders. I look forward to working with Anne as we build on the momentum w...
|
|
|
10.09.26 - 13:03
|
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program (Business Wire)
|
|
|
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project —
— Areas of Interest Expanded to Include Narcolepsy and Idiopathic Hypersomnia in Addition to Schizophrenia and Bipolar I Disorder —
— Stage One Submission Period Runs From Sept. 11, 2026 Through Oct. 16, 2026 —DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 11, 2026. Now in its ninth year, this competitive grant program is designed to support the next generation of researchers working on the front lines to advance our understanding of diseases in the field of neuroscience. Building on prior award cycles, the program will continue to accept applications related to schizophrenia, bipolar I disorder and the sleep and circadian disturbances associated with these conditions, while expanding its focus to include narcolepsy type 1 and 2 and idiopathic hypersomnia. The applicatio...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.07.26 - 13:03
|
Alkermes plc Reports Second Quarter 2026 Financial Results (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company's investor relations website at https://investor.alkermes.com.
Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today, to discuss these financial results and expectations, and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at https://investor.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfoli...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
